Preventing Illegal Laboratories and Protecting Public Health Act of 2026
- Bill Number
- S. 4227
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-03-26: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-04-13T18:48:39Z
AI-Generated Summary
Purpose
The "Preventing Illegal Laboratories and Protecting Public Health Act of 2026" aims to improve tracking of dangerous pathogens (highly pathogenic agents) sold or transferred by distributors to prevent misuse in illegal labs, and to strengthen federal oversight of high-security laboratories (high-containment laboratories) to enhance biosafety and biosecurity.
Key Provisions
- Logbook Program for Distributors (Section 2):
- Requires the Secretary of Health and Human Services (HHS), through the Assistant Secretary for Preparedness and Response, to create a program mandating "covered distributors" (entities selling, leasing, or transferring these agents) to maintain electronic logbooks.
- Logbooks must record: agent name, buyer details (name, address, phone, email, business info), intended use and storage location, dates/times/method of transfer, and buyer signature.
- Buyers must show government-issued photo ID (or equivalent) and verify details; distributors check and enter info.
- Logs kept for at least 3 years; successors inherit responsibility.
- Includes notice of criminal penalties for false entries (under 18 U.S.C. § 1001, up to 5 years imprisonment and fines).
- Secretary develops initial list of agents (risk group 3 or higher per NIH guidelines, excluding regulated "select agents") within 6 months, reviews annually, consulting agencies like CDC, NIH, DHS.
- Risk-based audits; restricted disclosure to authorized officials for compliance, health/safety, or security; exempt from Freedom of Information Act (FOIA).
- Internal university lab transfers exempt.
- High-Containment Lab Oversight (Section 3):
- National Security Advisor designates one federal entity for periodic strategic evaluations of labs handling biosafety level 3 (BSL-3) or higher pathogens (high-risk facilities requiring advanced containment).
- Evaluations assess: lab numbers/locations/missions, capacity/security/risks, oversight needs; develop national standards.
- Reports to President/Congress with recommendations on oversight gaps and lab utilization.
- Creates "Public Health Biosafety and Biosecurity Team" as single federal contact for state/local/Tribal/territorial agencies.
- Feasibility study for a database tracking lab owners, addresses, licenses, violations.
Significant Changes to Existing Law
- Introduces first-of-its-kind mandatory electronic logbooks for non-"select agent" highly pathogenic agents (previously unregulated beyond general guidelines).
- Does not override existing Federal Select Agent Program (stricter rules for top-risk agents/toxins).
- Establishes coordinated federal oversight and potential national database for high-containment labs, filling gaps in fragmented agency responsibilities.
Potential Impacts
- Government Agencies: Increases workload for HHS (list maintenance, audits), interagency coordination; new team/database could streamline info-sharing with states/locals.
- Citizens/Public Health: Reduces risks of pathogen misuse, lab accidents, or bioterrorism by improving tracking and oversight.
- Distributors/Buyers: Adds compliance costs/time (ID checks, logging); legitimate researchers face more paperwork but enhanced security.
- No direct international effects, but strengthens U.S. biosecurity standards.
Main Stakeholders
- Covered distributors (sellers of agents, including repositories/biobanks).
- Purchasers/buyers (labs, researchers, institutions).
- High-containment laboratories (BSL-3+ facilities, e.g., universities, government labs).
- Federal agencies (HHS/ASPR lead; CDC, NIH, DHS, others consulted).
- State/local/Tribal/territorial governments (access to info/team).
- Public (indirectly protected from biosafety risks).
Notable Legal, Constitutional, or Political Implications
- Legal: Makes false logbook entries a federal crime (18 U.S.C. § 1001); FOIA exemption protects sensitive data but limits public transparency; electronic signatures allowed under existing e-sign law.
- Constitutional: Balances public safety with privacy (restricted disclosures prevent misuse); no clear First/Fourth Amendment conflicts as voluntary compliance for sales.
- Political: Bipartisan (introduced by Sens. Cortez Masto and Banks); promotes unified biosecurity amid lab incident concerns, without new funding specified (implementation via existing authorities).
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Cortez Masto, Catherine [D-NV]
Cosponsors (1)
Recent Actions
- 2026-03-26: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2026-03-26: Introduced in Senate
Bill Versions
- Preventing Illegal Laboratories and Protecting Public Health Act of 2026 — issued 2026-03-26 — PDF (14 pages)